15 unchanged sentences
Issuer Purchases of Equity Securities
−Removed: The table below reflects shares of Common Stock we repurchased under the share repurchase program approved in November 2019, as well as Common Stock withheld by us for employees to satisfy their tax withholding obligations arising upon the vesting of restricted stock granted under one of our long-term incentive plans, during the three months ended December 31, 2020.
+Added: The table below reflects shares of Common Stock we repurchased under our share repurchase programs, as well as Common Stock withheld by us for employees to satisfy their tax withholding obligations arising upon the vesting of restricted stock granted under one of our long-term incentive plans, during the three months ended December 31, 2021.
Refer to Part II, Item 7.
−Removed: "Management's Discussion and Analysis of Financial Condition and Results of Operations - Liquidity and Capital Resources - Share Repurchase Program " for further details of the share repurchase program.
−Removed: Period Total Number of Shares Purchased Average Price Paid per Share Total Number of Shares Purchased as Part of a Publicly Announced Program Approximate Dollar Value of Shares that May Yet Be Purchased Under the Program (b)
−Removed: 10/1/2020–10/31/2020 72,870 $ 556.23 72,870 $ 332,144,883
−Removed: 11/1/2020–11/30/2020 596,867 $ 524.36 596,867 $ 19,172,999
−Removed: 12/1/2020–12/31/2020 41,636 $ 516.76 36,854 —
−Removed: Total 711,373 (a)
−Removed: (a) The difference between the total number of shares purchased and the total number of shares purchased as part of a publicly announced program relates to Common Stock withheld by us for employees to satisfy their tax withholding obligations arising upon the vesting of restricted stock granted under one of our long-term incentive plans.
−Removed: (b) In January 2021, our board of directors authorized a new share repurchase program to repurchase up to $1.5 billion of our Common Stock.
−Removed: "Liquidity and Capital Resources - Share Repurchase Program" for further details.
−Removed: SELECTED FINANCIAL DATA
−Removed: The selected financial data set forth below for the years ended December 31, 2020, 2019, and 2018 and as of December 31, 2020 and 2019 are derived from and should be read in conjunction with our audited financial statements, including the notes thereto, included elsewhere in this report.
−Removed: Certain prior year amounts have been reclassified to conform to the current year's presentation, including revisions related to the change in presentation for certain amounts received from collaborators who are not deemed to be our customers;
−Removed: see Note 1 to our Consolidated Financial Statements for further details.
−Removed: Year Ended December 31,
−Removed: (In millions, except per share data) 2020 2019 2018 2017 2016
−Removed: Statement of Operations Data:
−Removed: Net product sales $ 5,567.6 $ 4,834.4 $ 4,106.2 $ 3,718.5 $ 3,338.4
−Removed: Sanofi and Bayer collaboration revenue 2,372.5 1,549.2 910.4 456.3 223.9
−Removed: Other revenue 557.0 174.0 129.0 82.7 68.3
−Removed: 8,497.1 6,557.6 5,145.6 4,257.5 3,630.6
−Removed: Research and development (1)
−Removed: 2,735.0 2,450.0 1,468.8 1,180.5 1,297.4
−Removed: Selling, general, and administrative 1,346.0 1,341.9 1,127.2 940.0 860.9
−Removed: Cost of goods sold 491.9 362.3 180.0 202.5 194.6
−Removed: Cost of collaboration and contract manufacturing 628.0 402.8 237.5 169.4 82.6
−Removed: Other operating (income) expense, net (280.4) (209.2) (402.3) (314.5) (135.6)
−Removed: 4,920.5 4,347.8 2,611.2 2,177.9 2,299.9
−Removed: Income from operations 3,576.6 2,209.8 2,534.4 2,079.6 1,330.7
−Removed: Other income (expense), net 233.8 219.3 19.1 (1.1) (0.9)
−Removed: Income before income taxes 3,810.4 2,429.1 2,553.5 2,078.5 1,329.8
−Removed: Income tax expense (2)
−Removed: 297.2 313.3 109.1 880.0 434.3
−Removed: Net income $ 3,513.2 $ 2,115.8 $ 2,444.4 $ 1,198.5 $ 895.5
−Removed: Net income per share - basic $ 32.65 $ 19.38 $ 22.65 $ 11.27 $ 8.55
−Removed: Net income per share - diluted $ 30.52 $ 18.46 $ 21.29 $ 10.34 $ 7.70
−Removed: As of December 31,
+Added: "Management's Discussion and Analysis of Financial Condition and Results of Operations - Liquidity and Capital Resources" for further details of our share repurchase programs.
+Added: Period Total Number of Shares Purchased Average Price Paid per Share Total Number of Shares Purchased as Part of Publicly Announced Programs Approximate Dollar Value of Shares that May Yet Be
+Added: Purchased Under the Programs
(in millions)
−Removed: Balance Sheet Data:
−Removed: Cash, cash equivalents, and marketable securities (current and non-current)
10/1/2021–10/31/2021 1,195,053 $ 560.51 1,195,053 $ 27.5
−Removed: Total assets $ 17,163.3 $ 14,805.2 $ 11,734.5 $ 8,764.3 $ 6,973.5
−Removed: Long-term debt (3)
−Removed: $ 1,978.5 — — — —
−Removed: Finance lease liabilities
+Added: 11/1/2021–11/30/2021 110,500 $ 645.90 110,500 $ 2,956.1 (b)
12/1/2021–12/31/2021 271,289 $ 643.03 176,000 $ 2,845.0
−Removed: Stockholders' equity $ 11,025.3 $ 11,089.7 $ 8,757.3 $ 6,144.1 $ 4,449.2
−Removed: (1) Research and development expenses for the year ended December 31, 2019 includes a $400.0 million up-front payment to Alnylam in connection with our collaboration agreement.
−Removed: See Part I, Item 1.
−Removed: "Collaboration, License, and Other Agreements - Alnylam") for further details.
−Removed: (2) As a result of the Tax Cuts and Jobs Act being signed into law in December 2017, income taxes for the year ended December 31, 2017 included a charge of $326.2 million related to the re-measurement of our U.S.
−Removed: net deferred tax assets at the lower enacted corporate tax rate.
−Removed: See Note 14 to our Consolidated Financial Statements for further details.
−Removed: (3) In 2020, the Company issued and sold senior unsecured notes.
−Removed: "Liquidity and Capital Resources - Issuance of Senior Notes" for further details.
+Added: Total 1,576,842 (a)
+Added: 1,481,553 (a)
+Added: (a) The difference between the total number of shares purchased and the total number of shares purchased as part of publicly announced programs relates to Common Stock withheld by us for employees to satisfy their tax withholding obligations arising upon the vesting of restricted stock granted under one of our long-term incentive plans.
+Added: (b) In November 2021, our board of directors authorized an additional share repurchase program to repurchase up to $3.0 billion of our Common Stock.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.